RT Journal Article
T1 Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.
A1 Cortés-Vicente, Elena
A1 Álvarez-Velasco, Rodrigo
A1 Pla-Junca, Francesc
A1 Rojas-Garcia, Ricard
A1 Paradas, Carmen
A1 Sevilla, Teresa
A1 Casasnovas, Carlos
A1 Gómez-Caravaca, María Teresa
A1 Pardo, Julio
A1 Ramos-Fransi, Alba
A1 Pelayo-Negro, Ana Lara
A1 Gutiérrez-Gutiérrez, Gerardo
A1 Turon-Sans, Janina
A1 López de Munain, Adolfo
A1 Guerrero-Sola, Antonio
A1 Jericó, Ivonne
A1 Martín, María Asunción
A1 Mendoza, María Dolores
A1 Morís, Germán
A1 Vélez-Gómez, Beatriz
A1 Garcia-Sobrino, Tania
A1 Pascual-Goñi, Elba
A1 Reyes-Leiva, David
A1 Illa, Isabel
A1 Gallardo, Eduard
AB To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were considered refractory when their MG Foundation of America post-interventional status (MGFA-PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug-refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA-PIS) at end of follow-up were studied. We included 990 patients from 15 hospitals. Eighty-four patients (68 of 842 anti-acetylcholine receptor [AChR], 5 of 26 anti-muscle-specific tyrosine kinase [MusK], 10 of 120 seronegative, and 1 of 2 double-seropositive patients) were drug refractory. Drug-refractory patients were more frequently women (p  In this study, 8.5% of MG patients were drug-refractory. New more specific drugs are needed to treat drug-refractory MG patients.
YR 2022
FD 2022-01-26
LK http://hdl.handle.net/10668/19730
UL http://hdl.handle.net/10668/19730
LA en
DS RISalud
RD Apr 7, 2025